**Supplementary Table 2 Baseline characteristics and liver events in the relapsed and nonrelapsed subgroups.**

| **Index** | **Nonrelapsed, *n* = 7** | **Relapsed, *n* = 32** | ***p*** |
| --- | --- | --- | --- |
| Duration of treatment, month | 12 (6, 24) | 12 (6, 18) | 0.592 |
| Male | 3 (42.9) | 17 (53.1) | 0.940 |
| Age, years | 51 ± 13.6 | 45 ± 10.0 | 0.154 |
| ALT, U/L | 25 ± 5 | 23 ± 6 | 0.195 |
| AST, U/L | 24 ± 5 | 20 ± 6 | 0.093 |
| PLT, ×109/L | 178 ± 66 | 188 ± 51 | 0.667 |
| HBV DNA, log10 IU/mL |  3.54 (3.01, 3.94) | 4.19 (3.61, 4.76) | 0.015 |
| APRI |  |  |  |
| BL | 0.54 (0.25, 0.57) | 0.28 (0,23, 0.42) | 0.162 |
| EOT | 0.55 (0.27, 0.63) | 0.29 (0.24, 0.43) | 0.128 |
| EOF | 0.78 (0.45, 1.05) | 0.66 (0.54, 0.84) | 0.572 |
| ΔAPRIEOF-EOT | 0.30 (0.23, 0.41) | 0.35 (0.26, 0.48) | 0.453 |
| FIB-4 |  |  |  |
| BL | 1.62 (0.89, 1.82) | 0.94 (0.67, 1.42) | 0.141 |
| EOT | 1.87 (1.06, 2.22) | 0.93 (0.74, 0.94) | 0.022 |
| EOF | 3.08 (2.44, 3.85) | 2.24 (1.70, 3.22) | 0.174 |
| ΔFIB-4EOF-EOT# | 1.53 (0.75, 1.83) | 1.21 (0.87, 1.88) | 0.798 |
| Liver nodules, /100 PY | 0.49 | 2.77 | 0.341 |
| Cirrhosis, /100 PY | 0.23 | 1.19 | 0.463 |

Data are median (IQR), unless otherwise specified. \*ΔAPRI EOF-EOT is the difference of APRI between the EOF and EOT; #ΔFIB-4 EOF-EOT is the difference of FIB-4 between the EOF and EOT. ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; BL, baseline; EOF, end of follow-up; EOT, end of treatment; FIB-4, fibrosis-4 index; PY, patient-years.